(RS)-2,3-dihydro-1H-phenalen-1-ylamine | 228246-72-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 非那烯类
• 英文名称: (RS)-2,3-dihydro-1H-phenalen-1-ylamine
• 英文别名: 2,3-dihydro-1H-phenalen-1-amine
• CAS: 228246-72-8
• 化学式: C₁₃H₁₃N
• 分子量: 183.253
• InChiKey: PJYIGONWNQJLJK-UHFFFAOYSA-N

物化性质

• 沸点：
  353.8±31.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (RS)-2,3-dihydro-1H-phenalen-1-ylamine 在 potassium carbonate 作用下， 以 乙醇 、 水 、 溶剂黄146 为溶剂， 反应 6.0h， 生成 (RS)-1-(2,3-dihydro-1H-phenalen-1-yl)-4-phenylamino-piperidine-4-carbonitrile
  参考文献：
  名称：

  Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties

  摘要：

  The development of 8-(2,3,3a,4,5,6-hexahydro-1H-phenalenl-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones 3 starting from (RS)-s-acenaphten-1-yl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 1 is reported. The synthesis and the binding affinities at human OFQ and opioid (mu, kappa, delta) receptors of the stereoisomers 3a-f are described. In vitro the most selective compound, (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1 H-phenalenl-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one 3c, was found to act as a full agonist at the OFQ receptor in the GTP gamma(35)S binding test. It turned out to be selective versus a variety of other neurotransmitter systems. When tested in vivo following intraperitoneal injection, compound 3c was found to decrease neophobia in a novel environment and to exhibit dose-dependent anxiolytic-like effects in the elevated plus-maze procedure, thus confirming the effects observed following intracerebroventricular infusion of the OFQ peptide in rat. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00171-9
• 作为产物：
  描述：

  2,3-二氢-1H-苯并-1-酮 在 镍 盐酸羟胺 、 sodium acetate 作用下， 以 甲醇 、 氨 、 水 为溶剂， 生成 (RS)-2,3-dihydro-1H-phenalen-1-ylamine
  参考文献：
  名称：

  1,3,8-triazaspiro[4,5]decan-4-one derivatives

  摘要：

  本发明涉及以下结构的化合物 ##STR1## 其中 R.sup.1 和 R.sup.2 分别独立地是氢、较低烷基、较低烷氧基或卤素；R.sup.3 是苯基，未取代或被较低烷基、CF.sub.3、较低烷氧基或卤素取代；R.sup.4 是氢、较低烷基、较低烯基、--C(O)-较低烷基、--C(O)-苯基、较低烷基-C(O)-苯基、较低烷基- C(O)O-较低烷基、较低烷三基二-C(O)O-较低烷基、羟基-较低烷基、较低烷基-O-较低烷基、较低烷基-CH(OH)CF.sub.3、苯基或苄基，R.sup.5 和 R.sup.6 分别独立地是氢、苯基、较低烷基或二较低烷基或 R.sup.5 和 R.sup.6 与其相结合的碳原子形成苯环，或 R.sup.5 和 R.sup.1 或 R.sup.2 中的一个与其相结合的碳原子形成饱和或不饱和的 6 个成员环，A 是 4-7 个成员的饱和环，它们的外消旋体和对映异构体，以及药学上可接受的酸盐，它们是 OFQ 受体的激动剂和/或拮抗剂。

  公开号：

  US06071925A1

文献信息

• 1,3,8-triazaspiro[4,5]decan-4-one derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06071925A1

  公开（公告）日：2000-06-06

  The present invention relates to compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each independently hydrogen, lower alkyl, lower alkoxy or halogen; R.sup.3 is phenyl, which is unsubstituted or substituted by lower alkyl, CF.sub.3, lower alkoxy or halogen; R.sup.4 is hydrogen, lower alkyl, lower alkenyl, --C(O)-lower alkyl, --C(O)-phenyl, lower alkyl-C(O)-phenyl, lower alkylene-C(O)O-lower alkyl, lower alkantriyl-di-C(O)O-lower alkyl, hydroxy-lower alkyl, lower alkyl-O-lower alkyl, lower alkyl-CH(OH)CF.sub.3, phenyl or benzyl, R.sup.5 and R.sup.6 are each independently hydrogen, phenyl, lower alkyl or di-lower alkyl or R.sup.5 and R.sup.6 together with the carbon atoms to which they are bound form a phenyl ring, or R.sup.5 and one of R.sup.1 or R.sup.2 together with the carbon atoms to which they are bound form a saturated or unsaturated 6 membered ring, A is a 4-7 membered saturated ring, their racemates and the enantiomers thereof, and the pharmaceutically acceptable acid addition salts thereof which are agonists and/or antagonists of the OFQ receptor.

  本发明涉及以下结构的化合物 ##STR1## 其中 R.sup.1 和 R.sup.2 分别独立地是氢、较低烷基、较低烷氧基或卤素；R.sup.3 是苯基，未取代或被较低烷基、CF.sub.3、较低烷氧基或卤素取代；R.sup.4 是氢、较低烷基、较低烯基、--C(O)-较低烷基、--C(O)-苯基、较低烷基-C(O)-苯基、较低烷基- C(O)O-较低烷基、较低烷三基二-C(O)O-较低烷基、羟基-较低烷基、较低烷基-O-较低烷基、较低烷基-CH(OH)CF.sub.3、苯基或苄基，R.sup.5 和 R.sup.6 分别独立地是氢、苯基、较低烷基或二较低烷基或 R.sup.5 和 R.sup.6 与其相结合的碳原子形成苯环，或 R.sup.5 和 R.sup.1 或 R.sup.2 中的一个与其相结合的碳原子形成饱和或不饱和的 6 个成员环，A 是 4-7 个成员的饱和环，它们的外消旋体和对映异构体，以及药学上可接受的酸盐，它们是 OFQ 受体的激动剂和/或拮抗剂。
• 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0856514B1

  公开（公告）日：2001-06-13
• AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS
  申请人：Phenex-FXR GmbH

  公开号：US20200131144A1

  公开（公告）日：2020-04-30

  The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.
• US6071925A
  申请人：——

  公开号：US6071925A

  公开（公告）日：2000-06-06
• Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties
  作者：J Wichmann

  DOI：10.1016/s0223-5234(00)00171-9

  日期：2000.9

  The development of 8-(2,3,3a,4,5,6-hexahydro-1H-phenalenl-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones 3 starting from (RS)-s-acenaphten-1-yl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 1 is reported. The synthesis and the binding affinities at human OFQ and opioid (mu, kappa, delta) receptors of the stereoisomers 3a-f are described. In vitro the most selective compound, (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1 H-phenalenl-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one 3c, was found to act as a full agonist at the OFQ receptor in the GTP gamma(35)S binding test. It turned out to be selective versus a variety of other neurotransmitter systems. When tested in vivo following intraperitoneal injection, compound 3c was found to decrease neophobia in a novel environment and to exhibit dose-dependent anxiolytic-like effects in the elevated plus-maze procedure, thus confirming the effects observed following intracerebroventricular infusion of the OFQ peptide in rat. (C) 2000 Editions scientifiques et medicales Elsevier SAS.